Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort

被引:15
作者
Komura, Kazumasa [1 ,2 ]
Fujiwara, Yuya [1 ]
Uchimoto, Taizo [3 ]
Saito, Kenkichi [1 ]
Tanda, Naoki [1 ]
Matsunaga, Tomohisa [4 ]
Ichihashi, Atsushi [5 ]
Tsutsumi, Takeshi [1 ]
Tsujino, Takuya [6 ]
Yoshikawa, Yuki [1 ]
Nishimoto, Yudai [7 ]
Takai, Tomoaki [6 ]
Minami, Koichiro [4 ]
Taniguchi, Kohei [2 ]
Tanaka, Tomohito [2 ]
Uehara, Hirofumi [1 ]
Hirano, Hajime [1 ]
Nomi, Hayahito [1 ]
Ibuki, Naokazu [1 ]
Takahara, Kiyoshi [8 ]
Inamoto, Teruo [1 ]
Azuma, Haruhito [1 ]
机构
[1] Osaka Med Coll, Dept Urol, Osaka 5698686, Japan
[2] Osaka Med Coll, Translat Res Program, Osaka 5698686, Japan
[3] Saiseikai Nakatsu Hosp, Dept Urol, Osaka 5300012, Japan
[4] Osaka Med Coll, Dept Urol, Mishima Minami Hosp, Osaka 5690856, Japan
[5] Aijinkai Takatsuki Hosp, Dept Urol, Osaka 5691192, Japan
[6] Brigham & Womens Hosp, Dept Surg, Div Urol, 75 Francis St, Boston, MA 02115 USA
[7] Hirakata Municipal Hosp, Dept Urol, Osaka 5731013, Japan
[8] Fujita Hlth Univ, Dept Urol, Sch Med, Nagoya, Aichi 4701192, Japan
基金
日本学术振兴会;
关键词
castration-resistant prostate cancer; abiraterone; enzalutamide; propensity score matched analysis; radiographic progression-free survival; sequential treatment; ANTITUMOR-ACTIVITY; CLINICAL ACTIVITY; PHASE-II; DOCETAXEL; ACETATE; THERAPY; TRIALS;
D O I
10.3390/jcm8081251
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is emerging evidence that radiographic progression-free survival (rPFS) is highly correlated with overall survival (OS), potentially serving as an indicator of treatment outcome for castration-resistant prostate cancer (CRPC). The objective of this study is to assess rPFS and prostate specific antigen (PSA) response in sequential treatment using androgen signaling inhibitors (ASIs) including abiraterone and enzalutamide in newly diagnosed CRPC. Methods: Propensity score matching was performed to reduce bias by confounding factors between first-line ASIs. The primary endpoints of the study included rPFS, time to PSA progression (TTPP), and PSA response. Results: A paired-matched group of 184 patients were identified. From the initiation of first-line ASIs, there was no significant difference in rPFS, TTPP, and PSA response between treatment arms. From the initiation of second-line ASIs, enzalutamide following abiraterone consistently exhibited longer rPFS (median: 7 and 15 months, p = 0.04), TTPP, and better PSA response compared to the reverse, whereas OS did not reach significance (median: 14 and 23 months, p = 0.35). Conclusion: Although the effect of ASIs as the first line was similar, the extent of cross-resistance might differ towards less resistance in enzalutamide following abiraterone than the reverse.
引用
收藏
页数:13
相关论文
共 40 条
  • [1] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    [J]. EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [2] Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment
    Badrising, Sushil
    van der Noort, Vincent
    van Oort, Inge M.
    van den Berg, H. Pieter
    Los, Maartje
    Hamberg, Paul
    Coenen, Jules L.
    van den Eertwegh, Alfons J. M.
    de Jong, Igle J.
    Kerver, Emile D.
    van Tinteren, Harm
    Bergman, Andries M.
    [J]. CANCER, 2014, 120 (07) : 968 - 975
  • [3] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [4] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
    Brasso, Klaus
    Thomsen, Frederik B.
    Schrader, Andres J.
    Schmid, Sebastian C.
    Lorente, David
    Retz, Margitta
    Merseburger, Axel S.
    von Klot, Christoph A.
    Boegemann, Martin
    de Bono, Johann
    [J]. EUROPEAN UROLOGY, 2015, 68 (02) : 317 - 324
  • [5] A randomized phase II cross-over study of abiraterone plus prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration resistant prostate cancer (mCRPC).
    Chi, Kim N.
    Annala, Matti
    Sunderland, Katherine
    Khalaf, Daniel
    Finch, Daygen
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Beja, Kevin
    Vandekerkhove, Gillian
    Gleave, Martin
    Wyatt, Alexander William
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Management of patients with advanced prostate cancer in the Asia Pacific region: "real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017
    Chiong, Edmund
    Murphy, Declan G.
    Akaza, Hideyuki
    Buchan, Nicholas C.
    Chung, Byung Ha
    Kanesvaran, Ravindran
    Khochikar, Makarand
    Letran, Jason
    Lojanapiwat, Bannakij
    Ng, Chi-fai
    Ong, Teng
    Pu, Yeong-Shiau
    Saad, Marniza
    Schubach, Kathryn
    Turkeri, Levent
    Umbas, Rainy
    Vu Le Chuyen
    Williams, Scott
    Ye, Ding-Wei
    Davis, Ian D.
    [J]. BJU INTERNATIONAL, 2019, 123 (01) : 22 - 34
  • [7] Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe
    de Bono, Johann S.
    Chowdhury, Simon
    Feyerabend, Susan
    Elliott, Tony
    Grande, Enrique
    Melhem-Bertrandt, Amal
    Baron, Benoit
    Hirmand, Mohammad
    Werbrouck, Patrick
    Fizazi, Karim
    [J]. EUROPEAN UROLOGY, 2018, 74 (01) : 37 - 45
  • [8] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [10] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary B.
    Chi, Kim N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) : 352 - 360